Media Contact

Christopher Needles
Manager, Strategic Communications
christopher [dot] needlesoicr [dot] on [dot] ca
Telephone: 416-673-8505

Visit the Media Centre

Back to About OICR

Category: News Releases

An archive of public announcements, including scientific discoveries, new funding, new partnerships and major events by OICR and its collaborators on OICR-funded research.

Ontario Institute for Cancer Research selected as coordinating centre for Canadian cancer clinical trials

Posted: April 25, 2013 In: News Releases

TORONTO, ON (April 25, 2013) – Dr. Nicole Onetto, Deputy Director and Chief Scientific Officer of the Ontario Institute for Cancer Research (OICR), today announced that OICR has been selected by the Canadian Partnership Against Cancer (CPAC) to develop the coordinating centre for the Canadian Cancer Clinical Trials Network (CCCTN). Dr. Janet Dancey, OICR’s Director of the High Impact Clinical Trials Program, will be the Scientific Director and lead the CCCTN coordinating centre. The collaborating organizations are the NCIC Clinical Trials Group and N2 (Network of Networks).

Read More

Source: Ontario Institute for Cancer Research selected as coordinating centre for Canadian cancer clinical trials

Permalink
Link:
OICR researcher receives Genome Canada award to develop software for personalized medicine

Posted: April 25, 2013 In: News Releases

TORONTO, ON (April 25, 2013) – The Ontario Institute for Cancer Research (OICR) and the Ontario Genomics Institute (OGI) today announced that Dr. Lincoln Stein, OICR’s Program Leader, Informatics and Bio-computing, has been awarded $250,000 through Genome Canada’s Bioinformatics and Computational Biology competition, in partnership with the Canadian Institutes of Health Research (CIHR). Dr. Stein and his colleague Dr.

Read More

Source: OICR researcher receives Genome Canada award to develop software for personalized medicine

Permalink
Link:
OICR enters collaboration with Janssen Inc. in the development of multi-centre clinical trials to identify improved prostate cancer biomarkers

Posted: April 22, 2013 In: News Releases

TORONTO, ON (April 22, 2013) — Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced a collaboration with Janssen Inc. to find and test new biomarkers to identify patients with hormone resistant prostate cancer at high risk for disease progression and biomarkers of response to therapy. These biomarkers could lead to more personalized treatments and fewer side effects for prostate cancer patients.

Read More

Source: OICR enters collaboration with Janssen Inc. in the development of multi-centre clinical trials to identify improved prostate cancer biomarkers

Permalink
Link:
Researchers use novel method to identify prognostic gene signatures for survival in breast and ovarian cancers

Posted: December 18, 2012 In: News Releases

Toronto, Dec. 18, 2012 – Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR), today announced that scientists at the Institute have developed a new computer-based method to identify gene signatures that can serve as prognostic biomarkers for cancer. The researchers, Drs. Guanming Wu, Research Associate, and Lincoln Stein, Platform Leader and Principal Investigator, Informatics and Bio-computing Platform, used this technique to discover gene expression signatures related to survival in breast and ovarian cancers.

Read More

Source:
OICR_NR December 18, 2012.pdf
(1 MB)

Permalink
Link:
Cancer scientists identify a new layer of complexity within human colon cancer, shed light on resistance to treatment

Posted: December 14, 2012 In: News Releases

NEWS RELEASE

Cancer scientists identify a new layer of complexity within human colon cancer, shed light on resistance to treatment

Read More

Source:
FINAL John Dick Science Dec 13 2012.pdf
(1 MB)

Permalink
Link:
ICGC launches four new projects in China

Posted: December 4, 2012 In: News Releases

ICGC launches four new projects in China

Toronto – December 4, 2012. The International Cancer Genome Consortium (ICGC) today announced four new projects in China to identify the genomic drivers in colorectal, esophageal, liver and nasopharyngeal cancers, helping lay the foundation for developing treatments tailored to patients’ individual needs. China is a founding member of the ICGC, having launched a gastric cancer project in 2008.

Read More

Source:
ICGC-NR-December2012-FINAL.pdf
(1 MB)

Permalink
Link:
OICR and MaRS Innovation announce funding for the development of Cellax™, a nanotechnology-based cancer drug

Posted: November 13, 2012 In: News Releases Commercialization
TORONTO, ON (November 13, 2012) — The Ontario Institute for Cancer Research (OICR) and MaRS Innovation (MI) today announced $1.5 million in funding from OICR over three years to further develop Cellax™, a nanoparticle drug that could offer an alternative to chemotherapy with fewer side effects.
“Cellax is promising because it provides a more targeted strategy for treating tumours, killing tumour cells while minimizing the effect on healthy tissue,” said Dr. Rima Al-awar, Director, OICR’s Medicinal Chemistry Platform.
Read More

Source:
Cellax_NR_November13-2012_FINALv2.pdf
(1 MB)

Permalink
Link:
Study reveals possible method of removing leukemia stem cells, preventing relapse of Acute Myeloid Leukemia

Posted: September 3, 2012 In: News Releases

Toronto, Sept. 3, 2012 - New research published today in the Journal of
Experimental Medicine may provide a new avenue for the treatment of Acute Myeloid
Leukemia (AML) and a solution to the high rate of disease relapse experienced by
patients. The study identified a protein interaction that limits the immune response
to AML and provides a method to disrupt it.

The study was led by Drs. Jean Wang, Affiliate Scientist at the Ontario Cancer
Institute (OCI), the research arm of the University Health Network’s Princess

Read More

Source:
Exp Med NR FINAL 3.pdf
(2 MB)

Permalink
Link:
CImTeC announces appointment of Bart Sullivan as CEO

Posted: July 16, 2012 In: News Releases

Sullivan brings wealth of experience in medical imaging field, strong strategic direction

LONDON (July 16, 2012) – The Centre for Imaging Technology Commercialization (CImTeC) is pleased to announce the appointment of Bart Sullivan as Chief Executive Officer, effective immediately.

Sullivan will provide strategic direction to CImTeC in achieving its vision of being a driving force in the advancement and growth of the Canadian medical imaging technology sector.

Read More

Permalink
Link:
OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers

Posted: June 7, 2012 In: News Releases Commercialization

Toronto, Ontario – June 7, 2012. The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin’s lymphoma.

Read More

Source:
Fluorinov Pharma news release FINAL.pdf
(1 MB)

Permalink
Link:

Annual Report 2011/12

Media Contact

Category: News Releases